Objective: To analyze gender-specific differences regarding clinical symptoms, referral patterns and tumor biology prior to initial diagnosis of urothelial carcinoma of the bladder (UCB). Methods: A consecutive series of patients with an initial diagnosis of UCB was included. All patients completed a questionnaire on demographics, clinical symptoms and referral patterns. Results: In total, 68 patients (50 men, 18 women) with newly diagnosed UCB at admission for transurethral resection of bladder tumors were recruited. Dysuria was more often observed in women (55.6 vs. 38.0%, p = 0.001). Direct consultation of the urologist was conducted by 84.0% of males and 66.7% of females (p = 0.120). One third of the women saw their general practitioner and/or gynecologist once or twice (p = 0.120) before referral to the urologist. Furthermore, women were significantly more often treated for urinary tract infections than men (61.1 vs. 20.0%, p = 0.005). Cystoscopy at first presentation to the urologist was more often performed in men than women (88.0 vs. 66.7%, p = 0.068), with a more favorable tumor detection rate at first cystoscopy in men (96.0 vs. 50.0%, p < 0.001). Conclusions: Delayed referral patterns might lead to deferred diagnosis of UCB and consequently to adverse outcome. Thus, primary care physicians might consider referring patients with bladder complaints to specialized care earlier.

Journal Section:
Editor's choice
Keywords:
Urinary bladder neoplasms, Carcinoma, Transitional cell, Sex characteristics, Referrals
1.
Scosyrev E, Trivedi D, Messing E: Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol 2010;20:404-408.
[PubMed]
https://doi.org/10.1097/MOU.0b013e32833c7a9b
2.
Burger M, Catto JW, Dalbagni G, et al: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-241.
[PubMed]
https://doi.org/10.1016/j.eururo.2012.07.033
3.
Cardenas-Turanzas M, Cooksley C, Pettaway CA, et al: Comparative outcomes of bladder cancer. Obstet Gynecol 2006;108:169-175.
[PubMed]
https://doi.org/10.1097/01.AOG.0000223885.25192.91
4.
Fajkovic H, Halpern JA, Cha EK, et al: Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29:457-463.
[PubMed]
https://doi.org/10.1007/s00345-011-0709-9
5.
Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Comploj E, Jeschke K, Tripolt C, Rauchenwald M: Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 2013;112:68-73.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2012.11661.x
6.
Edge SB, Byrd DR, Compton CC, et al: American Joint Committee on Cancer (AJCC) Staging Manual, ed 7. New York, Springer, 2010.
[PubMed]
https://doi.org/10.1245/s10434-010-0985-4
7.
Messing EM, Young TB, Hunt VB, et al: Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 1989;64:2361-2367.
[PubMed]
https://doi.org/10.1002/1097-0142(19891201)64:11<2361::AID-CNCR2820641128>3.0.CO;2-4
8.
Mariani AJ, Mariani MC, Macchioni C, et al: The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989;141:350-355.
[PubMed]
9.
Nieder AM, Lotan Y, Nuss GR, et al: Are patients with hematuria appropriately referred to urology? A multi-institutional questionnaire based survey. Urol Oncol 2010;28:500-503.
[PubMed]
https://doi.org/10.1016/j.urolonc.2008.10.018
10.
Månsson A, Anderson H, Colleen S: Time lag to diagnosis of bladder cancer - influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol 1993;27:363-369.
[PubMed]
https://doi.org/10.3109/00365599309180448
11.
Yafi FA, Aprikian AG, Tanguay S, et al: Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system. Can Urol Assoc J 2011;5:97-101.
[PubMed]
12.
Johnson EK, Diagnaul S, Zhang Y, et al: Patterns of hematuria referral to urologists: does a gender disparity exist? Urology 2008;72:498-502.
[PubMed]
https://doi.org/10.1016/j.urology.2008.01.086
13.
May M, Nitzke T, Helke C, Vogler H, Hoschke B: Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 2004;38:231-235.
[PubMed]
https://doi.org/10.1080/00365590410029141
14.
Kluth LA, Fajkovic H, Xylinas E, et al: Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013;31:1029-1036.
[PubMed]
https://doi.org/10.1007/s00345-012-0996-9
15.
Fernandez-Gomez J, Madero R, Solsona E, et al: Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-2203.
[PubMed]
https://doi.org/10.1016/j.juro.2009.07.016
16.
Palou J, Sylvester RJ, Faba OR, Parada R, Penã JA, Algaba F, Villavicencio H: Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118-125.
[PubMed]
https://doi.org/10.1016/j.eururo.2011.10.029
17.
Keck B, Ott OJ, Häberle L, et al: Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol 2013;31:1023-1028.
[PubMed]
https://doi.org/10.1007/s00345-012-0971-5
18.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006;49:466-475.
[PubMed]
https://doi.org/10.1016/j.eururo.2005.12.031
19.
Kluth LA, Rieken M, Xylinas E, et al: Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol DOI: 10.1016/ j.eururo.2013.11.040.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.11.040
20.
Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, Kiemeney LA: Gender differences in stage-adjusted bladder cancer survival. Urology 2000;55:876-880.
[PubMed]
https://doi.org/10.1016/S0090-4295(00)00523-9
21.
Horstmann M, Witthuhn R, Falk M, Stenzl A: Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008;5:385-394.
[PubMed]
https://doi.org/10.1016/j.genm.2008.11.002
22.
May M, Stief C, Brookman-May S, et al: Gender-dependent cancer-specific survival following radical cystectomy. World J Urol 2012;30:707-713.
[PubMed]
https://doi.org/10.1007/s00345-011-0773-1
23.
Otto W, May M, Fritsche HM, et al: Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2,500 patients with urothelial carcinoma of the bladder. Gend Med 2012;9:481-489.
[PubMed]
https://doi.org/10.1016/j.genm.2012.11.001
24.
Têtu B: Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;2:53-59.
[PubMed]
https://doi.org/10.1038/modpathol.2008.193
25.
Bassi PF, De Marco V, De Lisa A, et al: Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005;75:193-200.
[PubMed]
https://doi.org/10.1159/000087792
26.
Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juárez FM, Martín García B: NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001;66:185-190.
[PubMed]
https://doi.org/10.1159/000056612
27.
Sagnak L, Ersoy H, Gucuk O, et al: Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria. Urol Int 2011;87:35-41.
[PubMed]
https://doi.org/10.1159/000325376
28.
Vom Dorp F, Pal P, Tschirdewahn S, et al: Correlation of pathological and cytological-cytometric grading of transitional cell carcinoma of the urinary tract. Urol Int 2011;86:36-40.
[PubMed]
https://doi.org/10.1159/000321017
29.
Falebita OA, Lee G, Sweeney P: Urine cytology in the evaluation of urological malignancy revisited: is it still necessary? Urol Int 2010;84:45-49.
[PubMed]
https://doi.org/10.1159/000273465
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.